Trial Profile
An Open Label Multicenter, Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma With BRAFv600 Mutated and CDKN2A Loss and Expression of Rb and Treated by Vemurafenib
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Vemurafenib
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms OPTIMUM
- 04 May 2021 Results published in the Clinical Cancer Research
- 10 Jun 2019 Status changed to completed as per results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology